Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
|Videos|November 26, 2018
Recurrent HR+ Breast Cancer
Recurrent HR+ Breast Cancer
Advertisement
A 58-Year-Old Woman With Recurrent HR+ Breast Cancer
December 2013
- A 58-year-old postmenopausal woman was referred for further evaluation of a suspicious left-sided lesion found incidentally on routine mammogram
- MRI revealed a 4.3-cm lesion in her left breast
- PMH unremarkable
- She underwent lumpectomy with axillary staging
- Biopsy findings:
- Histology: lobular carcinoma, grade 2
- Hormone receptor status: ER+/ PR (-)
- HER2,IHC 1+
- OncotypeDx RS, 19
- Staging, T2N0M0
- ECOG 0
- She was started on adjuvant anastrozole
September 2018
- On routine follow-up, the patient reports increasing fatigue and intermittent bouts of abdominal pain with nausea
- CT with contrast showed several small lesions in the liver; biopsy confirmed metastatic disease.
- The patient was started on ribociclib; anastrozole was changed to fulvestrant
- Imaging at 3 and 6 months showed a partial response
Advertisement
Related to this article
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Erica S. Alexander, MD, highlights endovascular approaches to venous occlusion, including stenting and thrombolysis, for select patients with NETs.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
In a phase 1 trial, a single intratumoral injection of oncolytic virus SVV-001 with ipilimumab and nivolumab was safe in high-grade neuroendocrine cancers.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5